Tailoring mTOR-based therapy: molecular evidence and clinical challenges

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo)28(10),727–732 (1975).▪ Along with [2], this is one of the first original reports of the isolation of rapamycin.
  Medline CASGoogle Scholar
• 2  Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo)28(10),721–726 (1975).▪ Along with [1], this is one of the first original reports of the isolation of rapamycin.
  Medline CASGoogle Scholar
• 3  Galat A, Lane WS, Standaert RF, Schreiber SL. A rapamycin-selective 25-kDa immunophilin. Biochemistry31(8),2427–2434 (1992).
  Medline CASGoogle Scholar
• 4  Koltin Y, Faucette L, Bergsma DJ et al. Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol. Cell. Biol.11(3),1718–1723 (1991).
  Medline CASGoogle Scholar
• 5  Cafferkey R, Young PR, McLaughlin MM et al. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol. Cell. Biol.13(10),6012–6023 (1993).
  Medline CASGoogle Scholar
• 6  Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell73(3),585–596 (1993).
  Medline CASGoogle Scholar
• 7  Brown EJ, Albers MW, Shin TB et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature369(6483),756–758 (1994).▪▪ Seminal paper reporting the identification of mTOR in eukaryotes.
  Medline CASGoogle Scholar
• 8  Keith CT, Schreiber SL. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science270(5233),50–51 (1995).
  Medline CASGoogle Scholar
• 9  Chen J, Zheng XF, Brown EJ, Schreiber SL. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl Acad. Sci. USA92(11),4947–4951 (1995).
  Medline CASGoogle Scholar
• 10  Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science273(5272),239–242 (1996).
  Medline CASGoogle Scholar
• 11  Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell149(2),274–293 (2012).
  Medline CASGoogle Scholar
• 12  Takano A, Usui I, Haruta T et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol. Cell. Biol.21(15),5050–5062 (2001).
  Medline CASGoogle Scholar
• 13  Haruta T, Uno T, Kawahara J et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol. Endocrinol.14(6),783–794 (2000).
  Medline CASGoogle Scholar
• 14  Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science307(5712),1098–1101 (2005).▪▪ Authoritative paper showing for the first time that mTORC2 is able to activate Akt.
  Medline CASGoogle Scholar
• 15  Iaccarino G, Ciccarelli M, Sorriento D et al. AKT participates in endothelial dysfunction in hypertension. Circulation109(21),2587–2593 (2004).
  Medline CASGoogle Scholar
• 16  Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans.37(Pt 1),217–222 (2009).
  Medline CASGoogle Scholar
• 17  Teachey DT, Greiner R, Seif A et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br. J. Haematol.145(1),101–106 (2009).
  Medline CASGoogle Scholar
• 18  Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today12(3–4),112–124 (2007).
  Medline CASGoogle Scholar
• 19  Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res.76(3),412–417 (1995).▪ Important study showing in vitro the relevance of rapamycin in the inhibition of vascular smooth muscle cell proliferation.
  Medline CASGoogle Scholar
• 20  Morice WG, Brunn GJ, Wiederrecht G, Siekierka JJ, Abraham RT. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J. Biol. Chem.268(5),3734–3738 (1993).
  Medline CASGoogle Scholar
• 21  Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell22(2),159–168 (2006).
  Medline CASGoogle Scholar
• 22  Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest.98(10),2277–2283 (1996).
  Medline CASGoogle Scholar
• 23  Morris RE, Cao W, Huang X et al. Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant. Proc.27(1),430–431 (1995).
  Medline CASGoogle Scholar
• 24  Gallo R, Padurean A, Jayaraman T et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation99(16),2164–2170 (1999).▪ Significant and thorough study showing in vivo the importance of rapamycin in the inhibition of restenosis after angioplasty.
  Medline CASGoogle Scholar
• 25  Atkins MB, Yasothan U, Kirkpatrick P. Everolimus. Nat. Rev. Drug Discov.8(7),535–536 (2009).
  Medline CASGoogle Scholar
• 26  Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med.363(19),1801–1811 (2010).
  Medline CASGoogle Scholar
• 27  Jozwiak S, Stein K, Kotulska K. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Future Oncol.8(12),1515–1523 (2012).
  CASGoogle Scholar
• 28  Franz DN. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev. Anticancer Ther.11(8),1181–1192 (2011).
  Medline CASGoogle Scholar
• 29  Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med.366(6),520–529 (2012).
  Medline CASGoogle Scholar
• 30  O’Regan R. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J. Clin. Oncol.31, Suppl. Abstract 505 (2013).
  MedlineGoogle Scholar
• 31  Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22),2271–2281 (2007).▪ Important clinical study demonstrating that the rapalog temsirolimus is able to improve overall survival among patients with metastatic renal-cell carcinoma.
  Medline CASGoogle Scholar
• 32  Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol.27(23),3822–3829 (2009).
  Medline CASGoogle Scholar
• 33  Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a Phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int.49(1),209–216 (1996).
  Medline CASGoogle Scholar
• 34  Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci.4,51 (2011).
  Medline CASGoogle Scholar
• 35  Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin.59(2),111–137 (2009).
  MedlineGoogle Scholar
• 36  Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci. Signal2(67),pe24 (2009).
  MedlineGoogle Scholar
• 37  Thoreen CC, Kang SA, Chang JW et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem.284(12),8023–8032 (2009).
  Medline CASGoogle Scholar
• 38  Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl Acad. Sci. USA105(45),17414–17419 (2008).
  Medline CASGoogle Scholar
• 39  Di Nicolantonio F, Arena S, Tabernero J et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest.120(8),2858–2866 (2010).
  Medline CASGoogle Scholar
• 40  Carracedo A, Ma L, Teruya-Feldstein J et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest.118(9),3065–3074 (2008).▪ Noteworthy paper reporting the relevance of the mTORC1–MAPK feedback loop in human cancer.
  Medline CASGoogle Scholar
• 41  Zhao H, Cui K, Nie F et al. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Res. Treat.131(2),425–436 (2012).
  Medline CASGoogle Scholar
• 42  Perino A, Ghigo A, Ferrero E et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. Mol. Cell42(1),84–95 (2011).
  Medline CASGoogle Scholar
• 43  Delbaldo C, Albert S, Dreyer C et al. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Target Oncol.6(2),119–124 (2011).
  MedlineGoogle Scholar
• 44  Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA98(18),10314–10319 (2001).
  Medline CASGoogle Scholar
• 45  Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res.68(18),7409–7418 (2008).
  Medline CASGoogle Scholar
• 46  Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol.23(23),5347–5356 (2005).
  Medline CASGoogle Scholar
• 47  Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med.8(2),128–135 (2002).
  Medline CASGoogle Scholar
• 48  Aguirre D, Boya P, Bellet D et al. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis9(6),797–805 (2004).
  Medline CASGoogle Scholar
• 49  Totary-Jain H, Sanoudou D, Dautriche CN, Schneller H, Zambrana L, Marks AR. Rapamycin resistance is linked to defective regulation of Skp2. Cancer Res.72(7),1836–1843 (2012).
  Medline CASGoogle Scholar
• 50  Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell148(6),1172–1187 (2012).
  Medline CASGoogle Scholar
• 51  Shomron N. MicroRNAs and pharmacogenomics. Pharmacogenomics11(5),629–632 (2010).
  CASGoogle Scholar
• 52  Cavarretta E, Chiariello GA, Condorelli G. Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. Eur. Heart J. (2013) (Epub ahead of print).
  MedlineGoogle Scholar
• 53  Totary-Jain H, Sanoudou D, Ben-Dov IZ et al. Reprogramming of the microRNA transcriptome mediates resistance to rapamycin. J. Biol. Chem.288(9),6034–44 (2013).▪ Original report identifying miRNAs as new downstream components of the mTOR signaling pathway.
  Medline CASGoogle Scholar
• 54  Totary-Jain H, Marks AR. MicroRNAs and the cellular response to rapamycin: potential role in diagnosis and therapy. Cell Cycle12(6),861–862 (2013).
  Medline CASGoogle Scholar
• 55  Li C, Liu Y, Liu J et al. Rapamycin inhibits human glioma cell proliferation through down-regulating mammalian target of rapamycin pathway and up-regulating microRNA-143. Head Neck Oncol.4(3),66 (2012).
  Medline CASGoogle Scholar
• 56  Liu L, Gong L, Zhang Y, Li N. Glycolysis in Panc-1 human pancreatic cancer cells is inhibited by everolimus. Exp. Ther. Med.5(1),338–342 (2013).
  Medline CASGoogle Scholar
• 57  Jin XL, Sun QS, Liu F et al. microRNA 21-mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation. J. Cell. Biochem.114(7),1625–1633 (2013).
  Medline CASGoogle Scholar
• 58  Sun Y, Ge Y, Drnevich J, Zhao Y, Band M, Chen J. Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J. Cell. Biol.189(7),1157–1169 (2010).
  Medline CASGoogle Scholar
• 59  Ge Y, Sun Y, Chen J. IGF-II is regulated by microRNA-125b in skeletal myogenesis. J. Cell. Biol.192(1),69–81 (2011).
  Medline CASGoogle Scholar
• 60  Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology55(6),1852–1862 (2012).
  Medline CASGoogle Scholar
• 61  Cui L, Zhou H, Zhao H et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer12,546 (2012).
  Medline CASGoogle Scholar
• 62  Yan B, Fu Q, Lai L et al. Downregulation of microRNA 99a in oral squamous cell carcinomas contributes to the growth and survival of oral cancer cells. Mol. Med. Rep.6(3),675–681 (2012).
  Medline CASGoogle Scholar
• 63  Wang Y, Liu J, Liu C, Naji A, Stoffers DA. MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic β-cells. Diabetes62(3),887–895 (2013).
  Medline CASGoogle Scholar
• 64  Oneyama C, Ikeda J, Okuzaki D et al. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene30(32),3489–3501 (2011).
  Medline CASGoogle Scholar
• 65  Iwaya T, Yokobori T, Nishida N et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis33(12),2391–2397 (2012).
  Medline CASGoogle Scholar
• 66  Uesugi A, Kozaki K, Tsuruta T et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res.71(17),5765–5778 (2011).
  Medline CASGoogle Scholar
• 67  Grundmann S, Hans FP, Kinniry S et al. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation123(9),999–1009 (2011).
  Medline CASGoogle Scholar
• 68  Nagaraja AK, Creighton CJ, Yu Z et al. A link between miR-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol. Endocrinol.24(2),447–463 (2010).
  Medline CASGoogle Scholar
• 69  Wang FZ, Weber F, Croce C, Liu CG, Liao X, Pellett PE. Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication. J. Virol.82(18),9065–9074 (2008).
  Medline CASGoogle Scholar
• 70  Doghman M, El Wakil A, Cardinaud B et al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res.70(11),4666–4675 (2010).
  Medline CASGoogle Scholar
• 71  Sun J, Chen Z, Tan X et al. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med. Oncol.30(1),411 (2013).
  MedlineGoogle Scholar
• 72  Merkel O, Hamacher F, Laimer D et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc. Natl Acad. Sci. USA107(37),16228–16233 (2010).
  Medline CASGoogle Scholar
• 73  Fornari F, Milazzo M, Chieco P et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res.70(12),5184–5193 (2010).
  Medline CASGoogle Scholar
• 74  Bhagwat SV, Gokhale PC, Crew AP et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol. Cancer Ther.10(8),1394–1406 (2011).
  Medline CASGoogle Scholar
• 75  Gupta M, Hendrickson AE, Yun SS et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood119(2),476–487 (2012).
  Medline CASGoogle Scholar
• 76  Lewis GP, Chapin EA, Byun J, Luna G, Sherris D, Fisher SK. Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. Invest. Ophthalmol. Vis. Sci.50(9),4429–4435 (2009).▪ Excellent paper showing that the simultaneous targeting of mTORC1 and mTORC2 may represent an effective antilymphoma strategy.
  MedlineGoogle Scholar
• 77  Chresta CM, Davies BR, Hickson I et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res.70(1),288–298 (2010).
  Medline CASGoogle Scholar
• 78  Willems L, Chapuis N, Puissant A et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia26(6),1195–1202 (2012).
  Medline CASGoogle Scholar
• 79  Houghton PJ, Gorlick R, Kolb EA et al. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr. Blood Cancer58(2),191–199 (2012).
  MedlineGoogle Scholar
• 80  Naing A, Aghajanian C, Raymond E et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br. J. Cancer107(7),1093–1099 (2012).
  Medline CASGoogle Scholar
• 81  Garcia-Garcia C, Ibrahim YH, Serra V et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer. Res.18(9),2603–2612 (2012).
  Medline CASGoogle Scholar
• 82  Pike KG, Malagu K, Hummersone MG et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg. Med. Chem. Lett.23(5),1212–1216 (2013).
  Medline CASGoogle Scholar
• 83  Maira SM, Finan P, Garcia-Echeverria C. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr. Top. Microbiol. Immunol.347,209–239 (2010).
  Medline CASGoogle Scholar
• 84  Venkatesan AM, Dehnhardt CM, Delos Santos E et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5´-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J. Med. Chem.53(6),2636–2645 (2010).
  Medline CASGoogle Scholar
• 85  Ghadimi MP, Lopez G, Torres KE et al. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol. Cancer Ther.11(8),1758–1769 (2012).
  Medline CASGoogle Scholar
• 86  Yuan J, Mehta PP, Yin MJ et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol. Cancer Ther.10(11),2189–2199 (2011).
  Medline CASGoogle Scholar
• 87  Maira SM, Stauffer F, Brueggen J et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther.7(7),1851–1863 (2008).
  Medline CASGoogle Scholar
• 88  Chiarini F, Grimaldi C, Ricci F et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res.70(20),8097–8107 (2010).
  Medline CASGoogle Scholar
• 89  Cerniglia GJ, Karar J, Tyagi S et al. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol. Pharmacol.82(6),1230–1240 (2012).
  Medline CASGoogle Scholar
• 90  Thomas HE, Mercer CA, Carnevalli LS et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci. Transl. Med.4(139),139ra184 (2012).
  Google Scholar
• 91  Figlin RA, Kaufmann I, Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int. J. Cancer133(4),788–796 (2013).
  Medline CASGoogle Scholar
• 101  Clinicaltrials.gov. http://clinicaltrials.gov
  Google Scholar